CD274 and non-small cell lung carcinoma: In several randomized clinical trials, IO has shown a significant clinical benefit in comparison to platinum-based chemotherapy in patients with a metastatic NSCLC and PD-L1 expression over 50%; it has also been shown that there is a significant linear correlation in clinical outcome between the PD-L1 tumor proportion score (TPS) and the magnitude of benefit.